Skip to main content
Log in

Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

A bioequivalence study of two rabeprazole enteric-coated formulations was carried out in 20 healthy Chinese volunteers according to a single dose, two-sequence, crossover randomized design. The two formulations were administered in two treatment days, separated by a washout period of 7 days. Blood samples were collected at specified time intervals over 10 hours post-dosing. Plasma samples were separated and assayed for rabeprazole using a selective and sensitive HPLC method with UV detection. The pharmacokinetic parameters AUC0–T, AUCmax, Cmax, tmax, t1/2 and MRT were determined from plasma concentration-time profile of both formulations. ANOVA and two one-sided t test procedures showed no significant difference in log-transformed Cmax, AUC0–T AUC0–∞ while the 90% confidence interval (CI) of the ratio of the geometric means of their values were also used to assess bioequivalence between the two formulations. The results of this study indicated that the two rabeprazole formulations can be considered to be bioequivalent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Morii M., Hamatani K., Takeguchi N (1995): The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase. Biochem. Pharmcol., 49,1729–1734

    Article  CAS  Google Scholar 

  2. Prakash A., Faulds D. (1998): Rabeprazole. Drugs., 55,261–267

    Article  CAS  PubMed  Google Scholar 

  3. Carswell CI., Goa KL. (2001): Rabeprazole: an update of its use in acid-related disorders. Drugs., 61, 2327–2356.

    Article  CAS  PubMed  Google Scholar 

  4. Fuhr U., Jetter A. (2002): Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie., 57, 595–601.

    CAS  PubMed  Google Scholar 

  5. Hoyumpa AM., Trevino-Alanis H., Grimes I., Humphries TJ. (1999): Rabeprazole: pharmacokinetics in patients with stable, compensated cirrhosis. Clin Ther., 21, 691 -701

    Article  CAS  PubMed  Google Scholar 

  6. Keane WF., Swan SK., Grimes I., Humphries TJ. (1999): Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol., 39, 927–933

    Article  CAS  PubMed  Google Scholar 

  7. Nakai H., Shimamura Y., Kanazawa T., Yasuda S., Kayano M. (1994): Determination of a new H(+)-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl., 660, 211–220

    Article  CAS  PubMed  Google Scholar 

  8. Takakuwa S., Chiku S., Nakata H., Yuzuriha T., Mano N., Asakawa N. (1995): Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in beagle dog plasma and rat plasma. J Chromatogr B Biomed Appl., 673, 113–122.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, J., Jiang, W.M., Gao, X.L. et al. Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers. European Journal of Drug Metabolism and Pharmacokinetics 29, 103–106 (2004). https://doi.org/10.1007/BF03190583

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190583

Keywords

Navigation